'Pmx 290' diaporamas de présentation

Pharminox SAB - 23 March 2009

654 views • 47 slides

PMX 2058: Rationale for Recent Preclinical Evaluation

PMX 2058: Rationale for Recent Preclinical Evaluation. Review of existing xenograft data with PMX 290 and PMX 2058 Borderline to modest efficacy in the colon (HCT116), breast (MDA-MB-435) and renal (CAKI-1) xenografts studied. Other models more sensitive to PMX 2058? Mechanism of action

404 views • 21 slides

PMX 290 induces a G2/M cell cycle block

365 views • 19 slides

BACKUP SLIDES

224 views • 9 slides

RMM Update 020309

145 views • 6 slides

RMM Update 020209

121 views • 4 slides

Thioredoxin-targeted Experimental Anti-tumour Quinols Exert Cytotoxicty Following

Thioredoxin-targeted Experimental Anti-tumour Quinols Exert Cytotoxicty Following Activation of Apoptosis Signal-regulating Kinase 1. Charles S Matthews, Tracey D Bradshaw, Eng-Hui Chew, Thilo Hagen and Malcolm FG Stevens. Mechanism of Action: Inhibition of Thioredoxin.

111 views • 1 slides

Role of Endoplasmic Reticulum Stress in Mechanism of Action of Antitumor Quinols.

PMX 8098. Gene expression changes (>2) in HCT116 cells in response to PMX 290. ER Tracker. 4 3 2 1 0 -1 -2 -3 -4. Change in expression (LOG2). Merge. DDIT3 TRIB3 ASNS C20orf139 UPP1 DNAJB9 FGF19 DDIT4 SQSTM1 ATF3 GDF15 BIRC3 SLC7A11 MAP1LC3 PRO618 PPP1R15A KIAA1718

445 views • 1 slides